Literature DB >> 1712809

Cerebral vascular endothelial cells are effective targets for in vitro lysis by encephalitogenic T lymphocytes.

R M McCarron1, M Racke, M Spatz, D E McFarlin.   

Abstract

Lysis of cerebral vascular endothelial cells (EC) by CD4-positive, myelin basic protein-specific encephalitogenic T cell lines was investigated. Unstimulated EC were not lysed, but culture in the presence of murine rIFN-gamma resulted in the expression of class II MHC (Ia) molecules and the concomitant ability to function as effective target cells for lysis. The possible requirement for Ia molecules was further demonstrated by antibody-blocking experiments. Lysis of EC targets also required the presence of specific Ag (myelin basic protein); PPD-specific T cell lines also lysed the PPD-pulsed EC. In all cases, lysis was directly proportional to E:T ratios. In addition, continuous passage of T cell lines resulted in the concomitant loss of encephalitogenicity and ability to affect EC lysis, indicating a possible relationship between these two factors. These results demonstrate that CD4+ T cells interact with cerebral vascular EC. It is suggested that such interactions may be important in the pathogenesis of diseases involving migrations of these cells across the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712809

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Major histocompatibility complex molecules on parenchymal cells of the target organ protect against autoimmune disease.

Authors:  Hui Shao; Henry J Kaplan; Deming Sun
Journal:  Chem Immunol Allergy       Date:  2007

Review 2.  Pathophysiology of the blood-brain barrier.

Authors:  K Selmaj
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Authors:  M K Racke; D E Scott; L Quigley; G S Gray; R Abe; C H June; P J Perrin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

4.  Immunomodulation in the treatment of multiple sclerosis and amyotrophic lateral sclerosis: a model for autoimmune disorders.

Authors:  K Alonso; R Medenica
Journal:  J Natl Med Assoc       Date:  1995-08       Impact factor: 1.798

5.  Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis.

Authors:  Helena S Domingues; Marsilius Mues; Hans Lassmann; Hartmut Wekerle; Gurumoorthy Krishnamoorthy
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

6.  Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia.

Authors:  K Kojima; T Berger; H Lassmann; D Hinze-Selch; Y Zhang; J Gehrmann; K Reske; H Wekerle; C Linington
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

7.  Costimulator deficient antigen presentation by an endothelial cell line induces a nonproliferative T cell activation response without anergy.

Authors:  J D St Louis; J A Lederer; A H Lichtman
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

8.  Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.

Authors:  R D Medenica; S Mukerjee; K Alonso; G Lazovic; T Huschart
Journal:  J Clin Apher       Date:  1994       Impact factor: 2.821

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.